miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta

Mahsa Tahmasebivand; Seyyed Reza Mousavi; Mehdi Khorrami; Hormoz Ayromlou; Reza Rikhtegar; Leila Saberi; Bahareh Khademi; Zahra Bahmanpour; Babak Emamalizadeh

doi:10.1016/j.jneuroim.2020.577212

miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta

J Neuroimmunol. 2020 Mar 7:342:577212. doi: 10.1016/j.jneuroim.2020.577212. Online ahead of print.

Authors

Mahsa Tahmasebivand¹, Seyyed Reza Mousavi¹, Mehdi Khorrami², Hormoz Ayromlou³, Reza Rikhtegar⁴, Leila Saberi², Bahareh Khademi¹, Zahra Bahmanpour¹, Babak Emamalizadeh⁵

Affiliations

¹ Immunology research center, Tabriz University of medical science, Tabriz, Iran; Department of Medical Genetics, Faculty of Medicine, Tabriz university of Medical Sciences, Tabriz, Iran.
² Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
³ Neurology Department, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
⁴ Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
⁵ Immunology research center, Tabriz University of medical science, Tabriz, Iran. Electronic address: emamalizadeh_b@yahoo.com.

PMID: 32199199
DOI: 10.1016/j.jneuroim.2020.577212

Abstract

Multiple sclerosis is immune-mediated disease of the central nervous system characterized by demyelination in axons. IFN-β is first-line treatment of MS. Biomarkers are needed for early prediction of responders and non-responders to therapy in the first month of treatment to avoid further disabilities. In this study, we analyzed the expression level of miR-504 and miR-711 in 52 IFN-β responder patients in comparison to 53 non-responders. In the next step, the in-silico analysis was used to enrich related signaling pathways. The expression level of miR-504 was significantly higher in patients who respond to IFN-β therapy, compared with non-responders and we obtain related statistically significant KEGG molecular signaling pathways. Our findings suggest that miR-504 can be considered as a novel biomarker for response to IFN-b therapy.

Keywords: Biomarker; Interferon-beta; Multiple sclerosis; miRNA.